| Abstrakt: |
B Results: b A total of 470 patients were screened with 316 meeting the inclusion/exclusion criteria evaluated; 122 patients in the baricitinib group and 194 patients in the tocilizumab group. Fifty-six (63.6%) patients achieved a plasma sodium of >= 130 mEq/L, and 20 (22.7%) patients achieved a plasma sodium of >= 135 mEq/L. Eighteen (20.5%) patients experienced a side effect or adverse event; the most common were sodium overcorrection in eight (9.1%) patients and gastrointestinal upset in seven (8%) patients. Pharmacists reduce medication errors at discharge by ensuring all home medications continued are appropriate, provide discharge counseling on new and existing medication therapies, and evaluate the safety and efficacy of the patient's medication therapy in order to decrease readmission rates. B Results: b Of the 43 included patients, 18 (41.9%) received a total of $37,019 in financial assistance, a median of $1296 per patient, which resulted in a median patient out-of- pocket reduction of $1,169 over the course of therapy. Among patients who developed VTE, 26 (72%) patients were actively receiving chemotherapy and 15 (42%) patients were obese. [Extracted from the article] |
Plný text